Research progress on molecular biomarkers of acute myeloid leukemia
Acute myeloid leukemia (AML) is the most common type of adult acute leukemia. The pathophysiology of the disease has been studied intensively at the cellular and molecular levels. At present, cytogenetic markers are an important basis for the early diagnosis, prognostic stratification and treatment...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1078556/full |
| _version_ | 1811170321049321472 |
|---|---|
| author | Pei-Yuan Yin Pei-Yuan Yin Rui-Wen Wang Rui Jing Xing Li Jing-Hua Ma Kai-Min Li Hua Wang |
| author_facet | Pei-Yuan Yin Pei-Yuan Yin Rui-Wen Wang Rui Jing Xing Li Jing-Hua Ma Kai-Min Li Hua Wang |
| author_sort | Pei-Yuan Yin |
| collection | DOAJ |
| description | Acute myeloid leukemia (AML) is the most common type of adult acute leukemia. The pathophysiology of the disease has been studied intensively at the cellular and molecular levels. At present, cytogenetic markers are an important basis for the early diagnosis, prognostic stratification and treatment of AML. However, with the emergence of new technologies, the detection of other molecular markers, such as gene mutations and epigenetic changes, began to play important roles in evaluating the occurrence and development of diseases. Recent evidence shows that identifying new AML biomarkers contributes to a better understanding of the molecular mechanism of the disease and is essential for AML screening, diagnosis, prognosis monitoring, and individualized treatment response. In this review, we summarized the promising AML biomarkers from four aspects, which contributing to a better understanding of the disease. Of course, it must be soberly aware that we have not listed all biomarkers of AML. Anyway, the biomarkers we mentioned are representative. For example, mutations in TP53, FLT3, and ASXL1 suggest poor prognosis, low remission rate, short survival period, and often require allogeneic hematopoietic stem cell transplantation. The CEBPA double mutation, NPM1 and CBF mutation suggest that the prognosis is good, the remission rate is high, the survival period is long, and the effect of chemotherapy or autotherapy is good. As for other mutations mentioned in the article, they usually predict a moderate prognosis. All in all, we hope it could provide a reference for the precise diagnosis and treatment of AML. |
| first_indexed | 2024-04-10T16:56:08Z |
| format | Article |
| id | doaj.art-2e9a53a7cfd84ab7893110de4418f399 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T16:56:08Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-2e9a53a7cfd84ab7893110de4418f3992023-02-07T07:25:57ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-02-011310.3389/fonc.2023.10785561078556Research progress on molecular biomarkers of acute myeloid leukemiaPei-Yuan Yin0Pei-Yuan Yin1Rui-Wen Wang2Rui Jing3Xing Li4Jing-Hua Ma5Kai-Min Li6Hua Wang7Hematology Department, Yantai Affiliated Hospital, Binzhou Medical University, Yantai, Shandong, ChinaDepartment of Blood Supply, Yantai Center Blood Station, Yantai, Shandong, ChinaDepartment of Anesthesiology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, ChinaHematology Department, Yantai Affiliated Hospital, Binzhou Medical University, Yantai, Shandong, ChinaDepartment of Blood Supply, Yantai Center Blood Station, Yantai, Shandong, ChinaDepartment of Science and Education, Yantai Hospital of Traditional Chinese Medicine, Yantai, Shandong, ChinaHematology Department, Yantai Yuhuangding Hospital, Qingdao University, Yantai, Shandong, ChinaHematology Department, Yantai Affiliated Hospital, Binzhou Medical University, Yantai, Shandong, ChinaAcute myeloid leukemia (AML) is the most common type of adult acute leukemia. The pathophysiology of the disease has been studied intensively at the cellular and molecular levels. At present, cytogenetic markers are an important basis for the early diagnosis, prognostic stratification and treatment of AML. However, with the emergence of new technologies, the detection of other molecular markers, such as gene mutations and epigenetic changes, began to play important roles in evaluating the occurrence and development of diseases. Recent evidence shows that identifying new AML biomarkers contributes to a better understanding of the molecular mechanism of the disease and is essential for AML screening, diagnosis, prognosis monitoring, and individualized treatment response. In this review, we summarized the promising AML biomarkers from four aspects, which contributing to a better understanding of the disease. Of course, it must be soberly aware that we have not listed all biomarkers of AML. Anyway, the biomarkers we mentioned are representative. For example, mutations in TP53, FLT3, and ASXL1 suggest poor prognosis, low remission rate, short survival period, and often require allogeneic hematopoietic stem cell transplantation. The CEBPA double mutation, NPM1 and CBF mutation suggest that the prognosis is good, the remission rate is high, the survival period is long, and the effect of chemotherapy or autotherapy is good. As for other mutations mentioned in the article, they usually predict a moderate prognosis. All in all, we hope it could provide a reference for the precise diagnosis and treatment of AML.https://www.frontiersin.org/articles/10.3389/fonc.2023.1078556/fullacute myeloid leukemiabiomarkergene mutationchromosomeepigenetics |
| spellingShingle | Pei-Yuan Yin Pei-Yuan Yin Rui-Wen Wang Rui Jing Xing Li Jing-Hua Ma Kai-Min Li Hua Wang Research progress on molecular biomarkers of acute myeloid leukemia Frontiers in Oncology acute myeloid leukemia biomarker gene mutation chromosome epigenetics |
| title | Research progress on molecular biomarkers of acute myeloid leukemia |
| title_full | Research progress on molecular biomarkers of acute myeloid leukemia |
| title_fullStr | Research progress on molecular biomarkers of acute myeloid leukemia |
| title_full_unstemmed | Research progress on molecular biomarkers of acute myeloid leukemia |
| title_short | Research progress on molecular biomarkers of acute myeloid leukemia |
| title_sort | research progress on molecular biomarkers of acute myeloid leukemia |
| topic | acute myeloid leukemia biomarker gene mutation chromosome epigenetics |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1078556/full |
| work_keys_str_mv | AT peiyuanyin researchprogressonmolecularbiomarkersofacutemyeloidleukemia AT peiyuanyin researchprogressonmolecularbiomarkersofacutemyeloidleukemia AT ruiwenwang researchprogressonmolecularbiomarkersofacutemyeloidleukemia AT ruijing researchprogressonmolecularbiomarkersofacutemyeloidleukemia AT xingli researchprogressonmolecularbiomarkersofacutemyeloidleukemia AT jinghuama researchprogressonmolecularbiomarkersofacutemyeloidleukemia AT kaiminli researchprogressonmolecularbiomarkersofacutemyeloidleukemia AT huawang researchprogressonmolecularbiomarkersofacutemyeloidleukemia |